Tuesday, September 26, 2023


Biotechnology News Magazine

Varigard, LLC Awarded 3-Year Agreement With MAGNET GROUP

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

Varigard, LLC has announced a three-year agreement with Mid-Atlantic Group Network of Shared Services Cooperative, also known as “MAGNET GROUP”, one of the oldest non-profit cooperative group purchasing and shared services organizations in the country.

Varigard brings together the latest in advanced polymer technologies and personal protection products to deliver pathogen protection that has not been seen before in the medical community. All of Varigard’s formulated product lines have been proven to sequester pathogens on contact including SARS-CoV-2.

“Varigard’s agreement will provide patented hand sanitizing lotions and surface counter disinfectants with extended protection times for MAGNET GROUP member facilities. Through strategic partnerships, Varigard also offers MAGNET GROUP members innovative products aimed at controlling airborne pathogens. We are excited about the partnership with MAGNET GROUP and look forward to delivering these game-changing solutions for years to come.” Michael Paolillo, CEO, Varigard, LLC

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine